Mariko Hatakeyama

Summary

Affiliation: RIKEN Brain Science Institute
Country: Japan

Publications

  1. ncbi A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling
    Mariko Hatakeyama
    RIKEN Genomic Sciences Center, 1 7 22 Suehirocho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    Biochem J 373:451-63. 2003
  2. ncbi Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides
    Atsushi Suenaga
    Bioinformatics Group and Protein Research Group, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    J Biol Chem 280:1321-6. 2005
  3. ncbi Topological analysis of MAPK cascade for kinetic ErbB signaling
    Takashi Nakakuki
    Cellular Systems Biology Team, Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, Tsurumi ku, Yokohama, Kanagawa, Japan
    PLoS ONE 3:e1782. 2008
  4. ncbi Mutation of epidermal growth factor receptor is associated with MIG6 expression
    Takeshi Nagashima
    Cellular Systems Modeling Team, Computational Systems Biology Research Group, Advanced Computational Sciences Department, RIKEN Advanced Science Institute, Yokohama, Kanagawa, Japan
    FEBS J 276:5239-51. 2009
  5. ncbi Molecular dynamics simulations reveal that Tyr-317 phosphorylation reduces Shc binding affinity for phosphotyrosyl residues of epidermal growth factor receptor
    Atsushi Suenaga
    Computational and Experimental System Biology Group, RIKEN Genomic Sciences Center, Yokohama, Kanagawa 230 0046, Japan
    Biophys J 96:2278-88. 2009
  6. ncbi Tyr-317 phosphorylation increases Shc structural rigidity and reduces coupling of domain motions remote from the phosphorylation site as revealed by molecular dynamics simulations
    Atsushi Suenaga
    Bioinformatics Group, RIKEN Genomic Sciences Center, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
    J Biol Chem 279:4657-62. 2004
  7. ncbi Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells
    Takeshi Nagashima
    Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, Yokohama, Kanagawa 230 0045, Japan
    Cancer Genomics Proteomics 5:161-8. 2008
  8. ncbi Integrative genome-wide expression analysis bears evidence of estrogen receptor-independent transcription in heregulin-stimulated MCF-7 cells
    Takeshi Nagashima
    Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, RIKEN Yokohama Institute, Yokohama, Japan
    PLoS ONE 3:e1803. 2008
  9. ncbi Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation
    Takeshi Nagashima
    Cellular Systems Biology Team, Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Yokohama, Kanagawa 230 0045, Japan
    J Biol Chem 282:4045-56. 2007
  10. ncbi Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells
    Noriko Yumoto
    Cellular Systems Biology Team, Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa, 230 0045, Japan
    Mol Cell Biochem 285:165-71. 2006

Detail Information

Publications16

  1. ncbi A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling
    Mariko Hatakeyama
    RIKEN Genomic Sciences Center, 1 7 22 Suehirocho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    Biochem J 373:451-63. 2003
    ....
  2. ncbi Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides
    Atsushi Suenaga
    Bioinformatics Group and Protein Research Group, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    J Biol Chem 280:1321-6. 2005
    ..91. The total electrostatic solvation energy between the N-SH2 domain and P-peptide was the dominant factor for its binding affinity...
  3. ncbi Topological analysis of MAPK cascade for kinetic ErbB signaling
    Takashi Nakakuki
    Cellular Systems Biology Team, Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, Tsurumi ku, Yokohama, Kanagawa, Japan
    PLoS ONE 3:e1782. 2008
    ..Such characteristics of the signaling cause the preferential binding of the Grb2-SOS complex to heterodimer-mediated signaling molecules...
  4. ncbi Mutation of epidermal growth factor receptor is associated with MIG6 expression
    Takeshi Nagashima
    Cellular Systems Modeling Team, Computational Systems Biology Research Group, Advanced Computational Sciences Department, RIKEN Advanced Science Institute, Yokohama, Kanagawa, Japan
    FEBS J 276:5239-51. 2009
    ..Taking all the above together, an EGFR mutation can cause transcriptional changes to accommodate the activation potency of the original signaling pathway at the cellular level...
  5. ncbi Molecular dynamics simulations reveal that Tyr-317 phosphorylation reduces Shc binding affinity for phosphotyrosyl residues of epidermal growth factor receptor
    Atsushi Suenaga
    Computational and Experimental System Biology Group, RIKEN Genomic Sciences Center, Yokohama, Kanagawa 230 0046, Japan
    Biophys J 96:2278-88. 2009
    ..e., tyrosine phosphorylation of Shc within its linker region regulates the binding affinity of SH2 and PTB domains for phosphorylated Shc partners, with important implications for signaling dynamics...
  6. ncbi Tyr-317 phosphorylation increases Shc structural rigidity and reduces coupling of domain motions remote from the phosphorylation site as revealed by molecular dynamics simulations
    Atsushi Suenaga
    Bioinformatics Group, RIKEN Genomic Sciences Center, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
    J Biol Chem 279:4657-62. 2004
    ....
  7. ncbi Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells
    Takeshi Nagashima
    Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, Yokohama, Kanagawa 230 0045, Japan
    Cancer Genomics Proteomics 5:161-8. 2008
    ..05). The proteome datasets of EGF and HRG contain molecules that are related to Axon guidance, ErbB signaling and VEGF signaling at a high rate...
  8. ncbi Integrative genome-wide expression analysis bears evidence of estrogen receptor-independent transcription in heregulin-stimulated MCF-7 cells
    Takeshi Nagashima
    Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, RIKEN Yokohama Institute, Yokohama, Japan
    PLoS ONE 3:e1803. 2008
    ..6%) and 13 E2-regulated (30.8%) gene groups. These results indicated that while E2 and HRG may induce common TFs, the regulatory mechanisms that govern HRG- and E2-induced gene expression differ...
  9. ncbi Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation
    Takeshi Nagashima
    Cellular Systems Biology Team, Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Yokohama, Kanagawa 230 0045, Japan
    J Biol Chem 282:4045-56. 2007
    ....
  10. ncbi Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells
    Noriko Yumoto
    Cellular Systems Biology Team, Computational and Experimental Systems Biology Group, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa, 230 0045, Japan
    Mol Cell Biochem 285:165-71. 2006
    ..Thus, PP2A regulates the ERK activity in a cell-specific manner, and it is speculated that distinct regulation of PP2A in the ErbB4 receptor signalling pathway may cause a difference in progression of cancer phenotypes...
  11. ncbi OBIYagns: a grid-based biochemical simulator with a parameter estimator
    Shuhei Kimura
    Bioinformatics Group, RIKEN Genomic Sciences Center, 1-7-22 Suehirocho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
    Bioinformatics 20:1646-8. 2004
    ..AVAILABILITY: OBIYagns example models, methods and user guide are available at https://access.obigrid.org/yagns/ SUPPLEMENTARY INFORMATION: Please refer to Bioinformatics online...
  12. ncbi Molecular dynamics, free energy, and SPR analyses of the interactions between the SH2 domain of Grb2 and ErbB phosphotyrosyl peptides
    Atsushi Suenaga
    Bioinformatics Group, RIKEN Genomic Sciences Center, Yokohama, Kanagawa, Japan
    Biochemistry 42:5195-200. 2003
    ....
  13. ncbi System properties of ErbB receptor signaling for the understanding of cancer progression
    Mariko Hatakeyama
    Cellular Systems Biology Team, RIKEN Genomic Sciences Center, 1 7 22 Suehiro cho, Tsurumi ku, Yokohama, Kanagawa 230 0045, Japan
    Mol Biosyst 3:111-6. 2007
    ..Spatio-temporal analyses of the cellular process can explain the biochemical role of the receptor tyrosine kinases in cancer development from a system point of view...
  14. ncbi Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses
    Marc R Birtwistle
    Department of Chemical Engineering, University of Delaware, Newark, DE, USA
    Mol Syst Biol 3:144. 2007
    ..Sensitivity analysis leads to the hypothesis that ERK activation is robust to parameter perturbation at high ligand doses, while Akt activation is not...
  15. ncbi Compensation effect of the MAPK cascade on formation of phospho-protein gradients
    Takashi Naka
    Faculty of Information Science, Kyushu Sangyo University, Matsukadai 2 3 1, Higashi ku, Fukuoka 813 8503, Japan
    Biosystems 83:167-77. 2006
    ....
  16. ncbi Comparison of the characteristic of estrogenic action patterns of beta-HCH and heregulin beta1 in MCF-7 human breast cancer cells
    Mariko Hatakeyama
    Department of Environmental Toxicology and the Center for Environmental Health Sciences, University of California, Davis, CA 95616, USA
    J Biochem Mol Toxicol 16:209-19. 2002
    ..These differences may account for their differential sensitivities to 4-hydroxytamoxifen...